Raptor Pharmaceutical (RPTP) : 3 brokerage houses believe that Raptor Pharmaceutical (RPTP) is a Strong Buy at current levels. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Raptor Pharmaceutical (RPTP). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 5 Wall Street Analysts endorse the stock as a Buy with a rating of 1.8.
Raptor Pharmaceutical (RPTP) : Currently there are 5 street experts covering Raptor Pharmaceutical (RPTP) stock. The most bullish and bearish price target for the stock is $11 and $4 respectively for the short term. The average price target of all the analysts comes to $8.4. The estimated standard deviation from the target is $2.7.
For the current week, the company shares have a recommendation consensus of Buy. Also, Citigroup maintains its view on Raptor Pharmaceutical (NASDAQ:RPTP) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Citigroup raises the price target from $6 per share to $8 per share on Raptor Pharmaceutical . The rating by the firm was issued on August 9, 2016.
Raptor Pharmaceutical (NASDAQ:RPTP): The stock opened at $7.5 and touched an intraday high of $7.56 on Wednesday. During the day, the stock corrected to an intraday low of $7.33, however, the bulls stepped in and pushed the price higher to close in the green at $7.53 with a gain of 3.01% for the day. The total traded volume for the day was 753,913. The stock had closed at $7.31 in the previous trading session.
Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Companys product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the European Commission (EC), as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Companys pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. Its other product, Quinsair, is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.